Kelsey A Orrell - JoVE Visualize

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

Case Reports in Dermatology|March 30, 2026

Drug-Induced Melasma in Patients on 5-Alpha Reductase Inhibitors: A Case ReportHiba Elhaj, Kelsey A Orrell, Renée A Beach

Expert Opinion on Drug Safety|November 7, 2017

Skin cancer associated with commonly prescribed drugs: tumor necrosis factor alpha inhibitors (TNF-αIs), angiotensin-receptor blockers (ARBs), phosphodiesterase type 5 inhibitors (PDE5Is) and statins -weighing the evidenceBeatrice Nardone, Kelsey A Orrell, Paras P Vakharia, et al.

International Journal of Dermatology|January 24, 2020

Risks for noncutaneous second primary malignancy in cutaneous malignant melanoma survivors: an analysis of data from the Surveillance, Epidemiology, and End Results (SEER) programParas P Vakharia, Ryan C Kelm, Kelsey A Orrell, et al.

Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

Case Reports in Dermatology|March 30, 2026

Drug-Induced Melasma in Patients on 5-Alpha Reductase Inhibitors: A Case ReportHiba Elhaj, Kelsey A Orrell, Renée A Beach

Expert Opinion on Drug Safety|November 7, 2017

Skin cancer associated with commonly prescribed drugs: tumor necrosis factor alpha inhibitors (TNF-αIs), angiotensin-receptor blockers (ARBs), phosphodiesterase type 5 inhibitors (PDE5Is) and statins -weighing the evidenceBeatrice Nardone, Kelsey A Orrell, Paras P Vakharia, et al.

International Journal of Dermatology|January 24, 2020

Risks for noncutaneous second primary malignancy in cutaneous malignant melanoma survivors: an analysis of data from the Surveillance, Epidemiology, and End Results (SEER) programParas P Vakharia, Ryan C Kelm, Kelsey A Orrell, et al.

Pageof 1